Skip to main content

Table 5 Base-case direct health care cost results of five treatment strategies

From: Cost-effectiveness analysis of metformin+dipeptidyl peptidase-4 inhibitors compared to metformin+sulfonylureas for treatment of type 2 diabetes

  Medical Costs Costs per Hypoglycemia Event Costs per Cardiovascular Events Weight Gain Costs (transition costsa) Total Costs (without transition costsa)
Metformin monotherapy $24 $0 $141 $0 $165
Metformin+DPP-4i $3524 $0 $330 $0 $3854
Metformin+DPP-4i + Basal insulin $7170 $1 $366 $0 $7537
Metformin+SU $40 $4 $441 $148 $486
Metformin+SU + Basal insulin $3686 $1 $366 $0 $4054
  1. Acronyms: DPP-4i-dipeptidyl peptidase-4 inhibitors, SU-sulfonylureas
  2. a Transition cost was added only one time when patients transitioned from the metformin monotherapy state to the metformin+SU state